VivoSeq
Other

Human T-Lymphotropic Virus 1 Infectious Disease

2

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Human T-lymphotropic virus 1 infectious disease is an early-stage landscape with 2 programs across 2 companies. The most active players are Roche, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Rituximab

Roche

Phase 3
No programs
Approved1

Raltegravir

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 2 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)